1. Market Research
  2. > Pharmaceutical Market Trends
  3. > PhaseBio Pharmaceuticals, Inc. - Product Pipeline Review - 2015

PhaseBio Pharmaceuticals, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 31 pages

PhaseBio Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘PhaseBio Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the PhaseBio Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PhaseBio Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PhaseBio Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PhaseBio Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the PhaseBio Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate PhaseBio Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PhaseBio Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PhaseBio Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PhaseBio Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PhaseBio Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PhaseBio Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

PhaseBio Pharmaceuticals, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
PhaseBio Pharmaceuticals, Inc. Snapshot 5
PhaseBio Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
PhaseBio Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
PhaseBio Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
PhaseBio Pharmaceuticals, Inc. - Pipeline Products Glance 10
PhaseBio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
PhaseBio Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
PhaseBio Pharmaceuticals, Inc. - Drug Profiles 14
PB-1023 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
PB-1046 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
PE-0139 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
PB-1120 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Ultra Rapid Acting Insulin 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
PhaseBio Pharmaceuticals, Inc. - Pipeline Analysis 22
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Target 22
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 24
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 25
PhaseBio Pharmaceuticals, Inc. - Recent Pipeline Updates 26
PhaseBio Pharmaceuticals, Inc. - Dormant Projects 28
PhaseBio Pharmaceuticals, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31

List of Tables
PhaseBio Pharmaceuticals, Inc., Key Information 5
PhaseBio Pharmaceuticals, Inc., Key Facts 5
PhaseBio Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
PhaseBio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
PhaseBio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
PhaseBio Pharmaceuticals, Inc. - Phase II, 2015 10
PhaseBio Pharmaceuticals, Inc. - Phase I, 2015 11
PhaseBio Pharmaceuticals, Inc. - Preclinical, 2015 12
PhaseBio Pharmaceuticals, Inc. - Discovery, 2015 13
PhaseBio Pharmaceuticals, Inc. - Pipeline by Target, 2015 22
PhaseBio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 23
PhaseBio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 24
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 25
PhaseBio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 26
PhaseBio Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 28

List of Figures
PhaseBio Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
PhaseBio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
PhaseBio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
PhaseBio Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 22
PhaseBio Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 23
PhaseBio Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 24
PhaseBio Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.